Drug and Therapeutics Bulletin 2008;46:57-61; doi:10.1136/dtb.2008.07.0017
Copyright © 2008 by the BMJ Publishing Group Ltd.
Rituximab and 
abatacept for rheumatoid arthritis
Relevant BNF section: 10.1.3
Estimates from the UK indicate that around 0.5–1.0% of the population have rheumatoid arthritis.1 Here we assess the place of rituximab (MabThera – Roche Products Ltd) and 
abatacept (Orencia – Bristol-Myers-Squibb), drugs in two new classes, which are licensed for certain adults with the condition.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
- Full Text
- Full Text (PDF)
- Submit a response
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
-
Malignant disease and immunosuppression
-
Haematology (drugs and medicines)
-
Musculoskeletal and joint disorders
-
Immunology (including allergy)
- Rheumatology
Bookmark with
Register for email alerts
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
Coming soon!
The DTB archive back to 1962, volume 1, issue 1 will soon be available.
